338 related articles for article (PubMed ID: 28704384)
61. Conservative management of thyroglobulin-positive, nonlocalizable thyroid carcinoma.
Frank RW; Middleton L; Stack BC; Spencer HJ; Riggs AT; Bodenner DL
Head Neck; 2014 Feb; 36(2):155-7. PubMed ID: 23728951
[TBL] [Abstract][Full Text] [Related]
62. A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients.
Robenshtok E; Grewal RK; Fish S; Sabra M; Tuttle RM
Thyroid; 2013 Apr; 23(4):436-42. PubMed ID: 23067402
[TBL] [Abstract][Full Text] [Related]
63. Elevated serum thyroglobulin levels at the time of ablative radioactive iodine therapy indicate a worse prognosis in thyroid cancer: an Australian retrospective cohort study.
Matthews TJ; Chua E; Gargya A; Clark J; Gao K; Elliott M
J Laryngol Otol; 2016 Jul; 130 Suppl 4():S50-3. PubMed ID: 27488338
[TBL] [Abstract][Full Text] [Related]
64. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
Lee JI; Chung YJ; Cho BY; Chong S; Seok JW; Park SJ
Surgery; 2013 Jun; 153(6):828-35. PubMed ID: 23489940
[TBL] [Abstract][Full Text] [Related]
65. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients.
Webb RC; Howard RS; Stojadinovic A; Gaitonde DY; Wallace MK; Ahmed J; Burch HB
J Clin Endocrinol Metab; 2012 Aug; 97(8):2754-63. PubMed ID: 22639291
[TBL] [Abstract][Full Text] [Related]
66. Serial Thyroglobulin Variation Trend Shortly after Radioiodine Therapy in Poorly to Moderately Differentiated Recurrent Thyroid Cancer.
Li CX; Hou M; Ren C; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Jun; 38(3):351-5. PubMed ID: 27469925
[TBL] [Abstract][Full Text] [Related]
67. Optimization of serum thyroglobulin measured at different time points for prognostic evaluation in differentiated thyroid carcinoma patients.
Mutsuddy P; Jeon S; Yoo SW; Zhang Y; Chowdhury MSA; Kim J; Song HC; Bom HS; Min JJ; Kwon SY
Medicine (Baltimore); 2020 Apr; 99(14):e19652. PubMed ID: 32243397
[TBL] [Abstract][Full Text] [Related]
68. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract][Full Text] [Related]
69. Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature.
Zhang X; Liu DS; Luan ZS; Zhang F; Liu XH; Zhou W; Zhong SF; Lai H
Clin Transl Oncol; 2018 Jul; 20(7):928-935. PubMed ID: 29119458
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery.
Makarewicz J; Adamczewski Z; Knapska-Kucharska M; Lewiński A
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):485-9. PubMed ID: 17115345
[TBL] [Abstract][Full Text] [Related]
71. Integrin αvβ3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2.
Zhao D; Jin X; Li F; Liang J; Lin Y
J Nucl Med; 2012 Dec; 53(12):1872-7. PubMed ID: 23071350
[TBL] [Abstract][Full Text] [Related]
72. [Preablative serum thyroglobulin as predictor of disease-free survival in differentiated thyroid cancer].
Díaz RE; Véliz J; Wohllk N
Rev Med Chil; 2013 Dec; 141(12):1506-11. PubMed ID: 24728426
[TBL] [Abstract][Full Text] [Related]
73. Prognostic Implications of Preablation Stimulated Tg: A Retrospective Analysis of 2500 Thyroid Cancer Patients.
Tian T; Xu Y; Zhang X; Liu B
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4688-e4697. PubMed ID: 34143886
[TBL] [Abstract][Full Text] [Related]
74. Prediction of radioactive iodine remnant ablation failure in patients with differentiated thyroid cancer: A cohort study of 740 patients.
Prpic M; Kust D; Kruljac I; Kirigin LS; Jukic T; Dabelic N; Bolanca A; Kusic Z
Head Neck; 2017 Jan; 39(1):109-115. PubMed ID: 27459351
[TBL] [Abstract][Full Text] [Related]
75. Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer.
Tang X; Shi L; Zhao Z; Wang J; Yang R; Huang Y; Tang J; Chen Z; Wang F
Medicine (Baltimore); 2023 Jun; 102(24):e33878. PubMed ID: 37327310
[TBL] [Abstract][Full Text] [Related]
76. Radioactive iodine refractoriness in Middle Eastern differentiated thyroid cancer: clinical outcome and risk factor analysis.
Parvathareddy SK; Siraj AK; Siraj N; Ahmed SO; Al-Rasheed M; Qadri Z; Siddiqui K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Front Endocrinol (Lausanne); 2024; 15():1326976. PubMed ID: 38812819
[TBL] [Abstract][Full Text] [Related]
77. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma.
Gholamrezanezhad A; Saghari M; Mirpour S; Beiki D; Tarbiat A; Javan S; Abdollahzadeh J
Endokrynol Pol; 2007; 58(2):100-4. PubMed ID: 17578824
[TBL] [Abstract][Full Text] [Related]
78. Anti-thyroglobulin antibodies do not significantly increase the risk of finding iodine avid metastases on post-radioactive iodine ablation scan in low-risk thyroid cancer patients.
Nabhan F; Porter K; Senter L; Ringel MD
J Endocrinol Invest; 2017 Sep; 40(9):1015-1021. PubMed ID: 28510122
[TBL] [Abstract][Full Text] [Related]
79. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors.
Song HJ; Qiu ZL; Shen CT; Wei WJ; Luo QY
Eur J Endocrinol; 2015 Sep; 173(3):399-408. PubMed ID: 26104753
[TBL] [Abstract][Full Text] [Related]
80. Importance of measurement of thyroglobulin and anti-thyroglobulin antibodies in differentiated thyroid cancer.
Alagić-Smailbegović J; Kucukalić-Selimović E; Setić I; Bećirović M; Begović L
Coll Antropol; 2012 Nov; 36 Suppl 2():33-8. PubMed ID: 23397752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
